Low dose resveratrol ameliorates mitochondrial respiratory dysfunction and enhances cellular reprogramming

Yuki Mizuguchi, Hideyuki Hatakeyama, Kou Sueoka, Mamoru Tanaka, Yu ichi Goto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Mitochondrial disease is associated with a wide variety of clinical presentations, even among patients carrying heteroplasmic mitochondrial DNA (mtDNA) mutations, probably because of variations in mutant mtDNA proportions at the tissue and organ levels. Although several case reports and clinical trials have assessed the effectiveness of various types of drugs and supplements for the treatment of mitochondrial diseases, there are currently no cures for these conditions. In this study, we demonstrated for the first time that low dose resveratrol (RSV) ameliorated mitochondrial respiratory dysfunction in patient-derived fibroblasts carrying homoplasmic mtDNA mutations. Furthermore, low dose RSV also facilitated efficient cellular reprogramming of the patient-derived fibroblasts into induced pluripotent stem cells, partly due to improved cellular viability. Our results highlight the potential of RSV as a new therapeutic drug candidate for the treatment of mitochondrial diseases.

Original languageEnglish
JournalMitochondrion
DOIs
Publication statusAccepted/In press - 2016 Jul 7

Fingerprint

Mitochondrial Diseases
Mitochondrial DNA
Induced Pluripotent Stem Cells
Mutation
Pharmaceutical Preparations
Therapeutics
Fibroblasts
Clinical Trials
resveratrol
Cellular Reprogramming

Keywords

  • Mitochondrial disease
  • Mitochondrial respiratory dysfunction
  • Patient-derived induced pluripotent stem cells (iPSCs)
  • Resveratrol

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cell Biology

Cite this

Low dose resveratrol ameliorates mitochondrial respiratory dysfunction and enhances cellular reprogramming. / Mizuguchi, Yuki; Hatakeyama, Hideyuki; Sueoka, Kou; Tanaka, Mamoru; Goto, Yu ichi.

In: Mitochondrion, 07.07.2016.

Research output: Contribution to journalArticle

@article{06eb1a992c334704802e7dd76de8a3ce,
title = "Low dose resveratrol ameliorates mitochondrial respiratory dysfunction and enhances cellular reprogramming",
abstract = "Mitochondrial disease is associated with a wide variety of clinical presentations, even among patients carrying heteroplasmic mitochondrial DNA (mtDNA) mutations, probably because of variations in mutant mtDNA proportions at the tissue and organ levels. Although several case reports and clinical trials have assessed the effectiveness of various types of drugs and supplements for the treatment of mitochondrial diseases, there are currently no cures for these conditions. In this study, we demonstrated for the first time that low dose resveratrol (RSV) ameliorated mitochondrial respiratory dysfunction in patient-derived fibroblasts carrying homoplasmic mtDNA mutations. Furthermore, low dose RSV also facilitated efficient cellular reprogramming of the patient-derived fibroblasts into induced pluripotent stem cells, partly due to improved cellular viability. Our results highlight the potential of RSV as a new therapeutic drug candidate for the treatment of mitochondrial diseases.",
keywords = "Mitochondrial disease, Mitochondrial respiratory dysfunction, Patient-derived induced pluripotent stem cells (iPSCs), Resveratrol",
author = "Yuki Mizuguchi and Hideyuki Hatakeyama and Kou Sueoka and Mamoru Tanaka and Goto, {Yu ichi}",
year = "2016",
month = "7",
day = "7",
doi = "10.1016/j.mito.2016.12.006",
language = "English",
journal = "Mitochondrion",
issn = "1567-7249",
publisher = "Elsevier",

}

TY - JOUR

T1 - Low dose resveratrol ameliorates mitochondrial respiratory dysfunction and enhances cellular reprogramming

AU - Mizuguchi, Yuki

AU - Hatakeyama, Hideyuki

AU - Sueoka, Kou

AU - Tanaka, Mamoru

AU - Goto, Yu ichi

PY - 2016/7/7

Y1 - 2016/7/7

N2 - Mitochondrial disease is associated with a wide variety of clinical presentations, even among patients carrying heteroplasmic mitochondrial DNA (mtDNA) mutations, probably because of variations in mutant mtDNA proportions at the tissue and organ levels. Although several case reports and clinical trials have assessed the effectiveness of various types of drugs and supplements for the treatment of mitochondrial diseases, there are currently no cures for these conditions. In this study, we demonstrated for the first time that low dose resveratrol (RSV) ameliorated mitochondrial respiratory dysfunction in patient-derived fibroblasts carrying homoplasmic mtDNA mutations. Furthermore, low dose RSV also facilitated efficient cellular reprogramming of the patient-derived fibroblasts into induced pluripotent stem cells, partly due to improved cellular viability. Our results highlight the potential of RSV as a new therapeutic drug candidate for the treatment of mitochondrial diseases.

AB - Mitochondrial disease is associated with a wide variety of clinical presentations, even among patients carrying heteroplasmic mitochondrial DNA (mtDNA) mutations, probably because of variations in mutant mtDNA proportions at the tissue and organ levels. Although several case reports and clinical trials have assessed the effectiveness of various types of drugs and supplements for the treatment of mitochondrial diseases, there are currently no cures for these conditions. In this study, we demonstrated for the first time that low dose resveratrol (RSV) ameliorated mitochondrial respiratory dysfunction in patient-derived fibroblasts carrying homoplasmic mtDNA mutations. Furthermore, low dose RSV also facilitated efficient cellular reprogramming of the patient-derived fibroblasts into induced pluripotent stem cells, partly due to improved cellular viability. Our results highlight the potential of RSV as a new therapeutic drug candidate for the treatment of mitochondrial diseases.

KW - Mitochondrial disease

KW - Mitochondrial respiratory dysfunction

KW - Patient-derived induced pluripotent stem cells (iPSCs)

KW - Resveratrol

UR - http://www.scopus.com/inward/record.url?scp=85009881987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009881987&partnerID=8YFLogxK

U2 - 10.1016/j.mito.2016.12.006

DO - 10.1016/j.mito.2016.12.006

M3 - Article

JO - Mitochondrion

JF - Mitochondrion

SN - 1567-7249

ER -